OSLO and PHILADELPHIA – August 30, 2023 – DoMore Diagnostics, a leader in deep learning precision diagnostics for digital pathology, and Proscia®,
a leading provider of digital and computational pathology solutions,
have partnered to help pathologists predict outcomes for colorectal
cancer (CRC) patients. The collaboration paves the way for integrating
artificial intelligence (AI)-powered clinical decision support into
routine pathology workflows, unlocking new insights that can guide
increasingly precise treatment decisions and ensure patients receive
optimal care.
CRC is the third most common and second most deadly cancer worldwide[1].
While adjuvant chemotherapy may be provided after primary surgery to
prevent the disease from recurring, predicting when it will lead to
overtreatment can be challenging. Up to 90% of patients with stage II
and stage III cases do not realize any benefit from adjuvant
chemotherapy and only suffer side effects.[2]
The partnership paves the way for delivering an integrated solution
that combines DoMore Diagnostics’ CE-IVDD marked Histotype Px® Colorectal* digital biomarker with Proscia’s CE-IVDR marked Concentriq® Dx** enterprise pathology platform. Data previously published in The Lancet3 and Lancet Oncology4
demonstrated that Histotype Px Colorectal can successfully predict
outcomes for stage II and stage III CRC patients. Combined with tumor
and lymph node status, the test report provides information about
patients’ risk profile and 5-year cancer-specific survival to inform the
decision to use adjuvant chemotherapy.
“We have proven that Histotype Px Colorectal can offer valuable
insight to guide personalized treatment decisions and help improve
patient outcomes,” said Torbjørn Furuseth, MD, CEO and Co-founder of
DoMore Diagnostics. “We must now continue to integrate the algorithm
into pathologists’ routine operations for it to make the greatest
impact. As leading laboratories are increasingly turning to Proscia, our
partnership paves the way for accelerating its adoption.”
Concentriq Dx is an enterprise pathology platform that drives primary
diagnostic workflows for reference laboratories, hospitals, and health
systems of all sizes. It offers a compelling user experience that allows
pathologists to quickly transition away from the microscope and work
with speed and ease. An open platform, Concentriq Dx is designed to
integrate AI applications from Proscia, Proscia’s customers, and leading
third parties, including DoMore Diagnostics, into routine workflows so
that laboratories can realize the full promise of pathology’s
computational future at scale.
“Laboratories are increasingly demanding an open approach to digital
pathology,” said Stephan Fromme, Proscia’s Head of Strategic Alliances.
“They recognize that unlocking more utility for pathologists and
patients means tapping into the collective power of a growing number of
solutions. We look forward to adding Histotype Px Colorectal to our
ecosystem to help our users make increasingly personalized diagnoses
that can ultimately reduce overtreatment for more patients.”
To learn more about Concentriq Dx and see a demo of Histotype Px
Colorectal, visit Proscia at booth 7 on the third-floor foyer during the
35th European Congress of Pathology.
*Histotype Px is CE-marked under IVDD. For Research Use only outside the EU.
**Concentriq Dx is CE-marked under IVDR.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make
personalized treatment decisions simple and accessible for all cancer
patients. Its unique digital biomarkers predict patient outcomes from
routine tumor tissue slides and can be seamlessly integrated into
pathologists’ existing workflow. The lead product Histotype Px®
Colorectal is a CE-IVDD marked outcome prediction marker for stage II
and III colorectal adenocarcinoma that informs the decision of whether
to provide adjuvant chemotherapy following surgical resection of the
tumor.
For more information, please visit: www.domorediagnostics.com. LinkedIn. Lancet Oncology.
About Proscia
Proscia is a software company that is accelerating pathology’s
digital transformation to change the way we understand diseases like
cancer. Its Concentriq digital pathology platform and powerful AI
applications are advancing the 150-year-old standard of research and
diagnosis towards a data-driven discipline, unlocking new insights that
accelerate R&D, improve patient outcomes, and fulfill the promise of
precision care. Leading diagnostic laboratories and 14 of the top 20
pharmaceutical companies rely on Proscia’s software each day. For more
information, visit proscia.com.